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Dear Sir,
In patients with end-stage renal disease
dialysis-related amyloidosis (DRA), also
termed AB-amyloidosis referring to its pre-
cursor protein ß2-microglobulin (ß2m), has
been identified as an important cause of
morbidity. The pathogenesis of DRA re-
mains largely obscure. Uremia is undoubted-
ly a major precondition for this disorder, but
non-transplant renal replacement therapy
also affects precipitation of the disease. The
pathophysiological process underlying amy-
loidogenesis cannot be explained solely on
the basis of simple retention and deposition
of amyloid, but may also involve cell activa-
tion and generation of inflammatory media-
tors which consequently alter processing of
ß2m and favor its osteoarticular deposition
[1].
There is growing evidence that the bioin-
compatibility of maintenance hemodialysis
procedures is important in the pathogenesis
of DRA. Cuprophane dialysis membranes
are known to activate complement and cells,
to cause increased production of ß2m and to
augment uremic ß2m body burden [2]. On
the other hand highly permeable and bio-
compatible membranes eliminate ß2m, re-
duce circulating ß2m concentrations [3] and
postpone the development of the major clini-
cal manifestations of DRA [4]. In addition,
use of ultrapure dialysate has been shown to
lower the incidence of the ensuing carpal
tunnel syndrome [5]. The question, whether
or not the chemical composition of the dialy-
sate affects the pathogenesis of DRA, has not
been investigated in clinical studies. The
present prospective, randomized compari-
son was aimed to elucidate the effect of dif-
ferent dialysate buffers on circulating ß2m
concentrations in patients undergoing main-
tenance hemodialysis. Forty-one stable
chronic hemodialysis patients with end-stage
renal disease of different etiologies, main-
tained on acetate hemodialysis utilizing the
low-flux cellulose acetate membrane for at
least 2 years, were randomly assigned to 4
study groups: group A continued hemodialy-
sis on acetate dialysate and cellulose acetate
membranes (FB130, surface area 1.3 m2,
Baxter, Ill., USA); group B remained on ace-
tate dialysate but changed to a high flux poly-
sulfone membrane (F60, surface area 1.25
m2, Fresenius, Oberursel, Germany); group
C changed to bicarbonate dialysate but re-
mained on a low-flux cellulose acetate mem-
brane, and group D was treated with bicar-
bonate dialysate and a high-flux polysulfone
membrane. Hemodialysis was performed
three times a week for 4–5 h (MTS A 2008 C
delivery system, Fresenius); nominal dialy-
sate flow rate was 500 ml/min, blood flow
rates ranged from 200 to 250 ml/min, fluid
removal rate was adjusted to clinical needs.
The chemical composition of the dialysates
used were identical in terms of calcium,
magnesium, and glucose concentration, but
contained either acetate (35 mmol/l) or bi-
carbonate (32 mmol/l). The sodium and po-
tassium concentrations were adjusted to the
patient’s values. Throughout the study the
individual hemodialysis regime remained
unchanged. Serum levels of ß2m were deter-
mined using routine laboratory methods.
There were no statistically significant dif-
ferences in the demographic characteristics
of the 4 groups of anuric patients at recruit-
ment (table 1). Circulating ß2m levels were
markedly elevated in all patients at baseline,
but they took different courses during the
study period of 1 year follow-up. Continua-
tion of the previous regimen of acetate dialy-
sate and cellulose acetate membrane resulted
in constant ß2m levels. The introduction of
high-flux polysulfone membranes to patients
receiving acetate dialysis caused a significant
reduction in serum ß2m. A more pro-
nounced fall in serum ß2m was noted in
patients treated with polysulfone mem-
branes. However, by comparison with pa-
tients receiving bicarbonate dialysis, pa-
tients treated with acetate dialysates had sig-
nificantly higher serum ß2m levels (table 2).
Our investigation demonstrates that the
choice of dialysate buffer affects circulating
ß2m levels independent of the biocompati-
bility and permeability of the dialyzer mem-
brane used. The previously published notion
that exposure of patient’s blood to acetate
dialysate for 1 or 6 weeks resulted in elevated
serum ß2m concentrations [6] is confirmed
and extended by our data. Higher circulating
ß2m levels in response to acetate dialysate
may be explained at least by two different
causes. Under the condition of hemodialysis
these mechanisms may not operate separate-
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Table 1. Characteristics of patients at recruitment
Group Membrane Dialysate
buffer
Number
(f/m)
Age,years
(range)
Time on HD1
months (range)
Urine volume1
ml/day (range)
CA acetate 9 (6/3) 50.3 (29–72) 43.7B13.8 (26–62) 52.2B35.2 (0–100)
B CA bicarbonate 10 (6/4) 51.8 (35–66) 43.3B15.4 (26–72) 23.6B33.3 (0–100)
C PS acetate 11 (6/5) 52.4 (28–71) 40.5B19.8 (19–81) 36.4B37.5 (0–100)
D PS bicarbonate 11 (7/4) 52.8 (36–66) 39.7B11.8 (19–56) 27.3B40.0 (0–100)
CA = Cellulose acetate; PS = polysulfone; HD = hemodialysis.
1 Mean B SD.
Table 2. Serum ß2m levels (mean b SD)
in the 4 treatment groups: effects of porosity
of dialysis membrane and of dialysate
buffer
Group Membrane Dialysate
buffer
Serum ß2m levels, mg/l
0 months 6 months 12 months
CA acetate 50.2B7.5 51.6B5.8 51.7B5.8
B CA bicarbonate 49.8B8.7 46.5B7.3 46.2B9.9*
C PS acetate 50.1B8.5 39.2B6.5 41.6B8.5
D PS bicarbonate 48.8B7.9 33.5B6.9 31.7B7.2*
CA = Cellulose acetate; PS = polysulfone.
* p ! 0.05 vs. corresponding values of patients on acetate dialysate.
ly but synergistically. First, Sonikian et al.
[6] performed in vitro and in vivo studies
indicating that metabolic acidosis enhances
ß2m generation and release. Secondly, ace-
tate may exert a direct effect on monocytes
or lymphocytes or may induce the liberation
of inflammatory mediators such as cytokines
or growth factors, which stimulate ß2m syn-
thesis by these cells [7–10].
Our observations have clinical implica-
tions, because at present there is no causal
therapy for established DRA. It would be
prudent to recommend the use of highly
permeable, biocompatible dialyzer mem-
branes in combination with sterile bicarbon-
ate dialysate to postpone DRA in those pa-
tients at increased risk of this disorder:
namely all patients who have no chance of
receiving a kidney transplant and patients
over 55 years.
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